Avantogen’s CEO joins Hawaii Biotech Board of Directors
Avantogen is a significant investor in Hawaii Biotech and intends to purchase additional shares in the company based on proceeds received from Avantogen’s recent $1 million capital raising.
"The Board of Avantogen is firmly convinced that Hawaii Biotech's recombinant DNA manufacturing platform is an excellent investment opportunity, and Avantogen actively seeks to increase its stake in this promising vaccine development company," stated Avantogen Chairman Patrick Elliott.
Hawaii Biotech Inc recently announced initiation of a Phase I West Nile Virus vaccine clinical trial, development of partnerships with PDVI/Bill & Melinda Gates Foundation and the Walter Reed Army Institute of Research, and recruitment of Professor Ian Frazer to the Scientific Advisory Board of Hawaii Biotech Inc. Hawaii Biotech anticipates participating in a Walter Reed sponsored Phase I human clinical trial with their Dengue vaccine candidate early next calendar year.
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.